logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Cassava Sciences Product, Simufilam, Improved the Cognition and Behavior of Alzheimer's Patients Following Six Months of Treatment

Cassava Sciences Announced Simufilam Results for Alzheimer's Cassava Sciences ( SAVA ) announced impressive results of an interim analysis from an open-label study of simufilam, a drug candidate for the treatment of Alzheimer’s disease. Simufilam improved both patients’ cognition and...

Read More

February 2, 2021

0

Roche and Spark Therapeutics: Gene Therapy SPK-8016 Demonstrating Promising Results on Adults with Severe Hemophilia A

Roche Group and Spark Therapeutics Gene Therapy Showing Promising Results Looking for gene therapy treatments for chronic debilitating life-threatening diseases we fell on news from Spark Therapeutics, a member of the Roche Group ( RHHBY ) ;   the firm...

Read More

February 5, 2021

0

What Happened Over the Past Two Days and Biotech

Some Gains in Biotech Stocks During the War in Europe On Tuesday, Mar 8,2022 the United States’ government decided to ban the importation of Russian oil, liquefied natural gas and coal. This decision was made to further deprive Russia from...

Read More

March 10, 2022

0

Reata Pharmaceuticals: Good News for the Prohost Pick

Reata Pharmaceuticals Announcement Regarding the NDA for Omaveloxolone for Friedreich’s Ataxia Reata Pharmaceuticals (RETA) announced that the U.S. Food and Drug Administration ( FDA ) does not plan to hold an advisory committee meeting in connection with its review of...

Read More

October 14, 2022

0

Cassava Sciences: Significant Program Progress and its Expected Milestones for 2021

Cassava Sciences 2021 Focus and Momentum Cassava Sciences ( SAVA ) President & CEO, Remi Barbier, informed that the firm has started 2021 with tremendous momentum led by results of a 6-month interim analysis from an open-label study of simufilam...

Read More

February 8, 2021

0

Why Cassava Sciences Stock Opened Down Today. See Also: The Mirati Therapeutics and MD Anderson Collaboration

Cassava Sciences Inc Opened Down Today Cassava Sciences, Inc. ( SAVA ) - a clinical-stage biotech firm focused on the treatment of Alzheimer’s disease, announced that it has entered into a definitive agreement with several healthcare-focused, and other institutional investors, for...

Read More

February 10, 2021

0

Gilead and MacroGenics Announce Oncology Collaboration to Develop Promising Bispecific Antibodies

Gilead Sciences and MacroGenics Collaboration Announcement Gilead Sciences ( GILD ) and MacroGenics ( MGNX ) announced an exclusive option and collaboration agreement to develop MGD024 using MacroGenics DART® platform, and two additional bispecific research programs. The collaboration agreement grants...

Read More

October 17, 2022

0

bluebird bio Temporarily Suspends Studies of LentiGlobin Gene Therapy for SCD. See Also: Cellectis is Outperforming

bluebird bio Suspends LentiGlobin Studies bluebird bio ( BLUE ) placed its Phase 1/2 (HGB-206) and Phase 3 (HGB-210) studies of LentiGlobin gene therapy for sickle cell disease (SCD), bb1111, on a temporary suspension due to a reported Suspected Unexpected Serious...

Read More

February 17, 2021

0

Why IVERIC bio Rallied Today

IVERIC bio's Rally IVERIC Bio ( ISEE ) announced that the U.S. ( FDA ) has granted Breakthrough Therapy designation for avacincaptad pegol ( ACP ), also known as Zimura®. Zimura is a novel investigational complement C5 inhibitor aimed at treating...

Read More

November 18, 2022

0

Madrigal Pharmaceuticals and Akero Therapeutics: After Having No Treatment for NASH, We Now Have Two Products Expected to be Approved

Treatments for NASH Madrigal Pharmaceuticals ( MDGL ) is the second company after Akero Therapeutics ( AKRO ) to announce positive top-line late results for Nonalcoholic steatohepatitis (NASH). Its product resmetirom - a liver-directed selective thyroid hormone receptor agonist has...

Read More

December 19, 2022

0

  • Previous
  • 1
  • 2
  • ...
  • 131
  • 132
  • 133
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy